X4 Pharmaceuticals (XFOR) Assets Average (2018 - 2025)

X4 Pharmaceuticals' Assets Average history spans 8 years, with the latest figure at $227.0 million for Q4 2025.

  • For Q4 2025, Assets Average rose 39.86% year-over-year to $227.0 million; the TTM value through Dec 2025 reached $227.0 million, up 39.86%, while the annual FY2025 figure was $218.5 million, 48.76% up from the prior year.
  • Assets Average reached $227.0 million in Q4 2025 per XFOR's latest filing, up from $134.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $227.0 million in Q4 2025 to a low of $90.3 million in Q2 2022.
  • Average Assets Average over 5 years is $143.1 million, with a median of $139.1 million recorded in 2023.
  • Peak YoY movement for Assets Average: plummeted 40.32% in 2022, then soared 78.32% in 2023.
  • A 5-year view of Assets Average shows it stood at $118.8 million in 2021, then increased by 13.17% to $134.5 million in 2022, then grew by 19.17% to $160.3 million in 2023, then increased by 1.27% to $162.3 million in 2024, then surged by 39.86% to $227.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Assets Average are $227.0 million (Q4 2025), $134.4 million (Q3 2025), and $117.6 million (Q2 2025).